A Comprehensive Monograph on Testosterone Enanthate (DB13944)

Introduction and Drug Profile

Overview

Testosterone Enanthate is a synthetic, esterified derivative of the endogenous androgen, testosterone, and is classified as an anabolic-androgenic steroid (AAS).[1] Functionally, it serves as a long-acting prodrug, meaning it is inactive until metabolized within the body to release the active therapeutic agent, which in this case is bioidentical testosterone.[1] First introduced for medical use in 1954 by Squibb under the brand name Delatestryl, Testosterone Enanthate has since become a foundational component of androgen replacement therapy (ART) worldwide.[1] It is one of the most widely prescribed testosterone esters, alongside testosterone cypionate and testosterone undecanoate, for the management of male hypogonadism.[3]

The therapeutic efficacy of Testosterone Enanthate is not derived from the esterified compound itself but from the slow and sustained release of testosterone following its administration. This is achieved through the enzymatic cleavage of the enanthate ester moiety by esterases present in the bloodstream and tissues.[3] The compound is formulated as an injectable solution in an oil-based vehicle, which, when administered via intramuscular or subcutaneous injection, forms a depot or reservoir. This depot mechanism ensures a gradual release of the drug, prolonging its duration of action and allowing for less frequent dosing compared to unmodified testosterone.[3] This slow-release characteristic is central to its clinical utility, providing a practical method for long-term hormone replacement.

Physicochemical Properties and Identifiers

Testosterone Enanthate presents as a white or yellowish-white crystalline powder. It has a characteristic melting point range of 34-39°C.[1] Due to its lipophilic nature, it is formulated for parenteral administration in an oil vehicle, such as castor oil or sesame oil, which facilitates the depot effect upon injection.[3] It is soluble in various organic solvents, including ethanol, dimethyl sulfoxide (DMSO), and dimethylformamide (DMF).[2] The stability of the compound is notable, with a shelf life of at least five years under appropriate storage conditions (2-8°C).[1]

A comprehensive list of its chemical and regulatory identifiers is crucial for cross-referencing in various scientific and regulatory databases. These identifiers provide a standardized nomenclature for the compound, ensuring accuracy in research, clinical practice, and regulatory oversight.

Table 1.1: Chemical and Regulatory Identifiers for Testosterone Enanthate

Identifier Type	Value	Source(s)
IUPAC Name	phenanthren-17-yl] heptanoate	3
Common Name	Testosterone Enanthate	5
DrugBank ID	DB13944	3
CAS Number	315-37-7	3
Molecular Formula	C26​H40​O3​	5
InChIKey	VOCBWIIFXDYGNZ-IXKNJLPQSA-N	5
SMILES	CCCCCCC(=O)O[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CCC4=CC(=O)CC[C@]34C)C	5
UNII	7Z6522T8N9	3
ChEBI ID	CHEBI:9464	3
PubChem CID	9416	3

Comprehensive Pharmacological Profile

Mechanism of Action

The pharmacological activity of Testosterone Enanthate is entirely dependent on its conversion to testosterone. As a prodrug, it undergoes a critical activation step before it can exert any physiological effect.

Prodrug Activation

Upon intramuscular or subcutaneous injection, Testosterone Enanthate is slowly released from its oil depot into the systemic circulation. In the bloodstream and target tissues, ubiquitous esterase enzymes recognize and hydrolyze the ester bond at the 17-beta position of the steroid nucleus.[3] This enzymatic cleavage separates the enanthic acid (heptanoate) moiety from the testosterone molecule, releasing free, biologically active testosterone.[6] Because the released hormone is identical to endogenously produced testosterone, this form of therapy is considered a bioidentical hormone replacement.[3] The rate of this hydrolysis is the primary determinant of the drug's long duration of action.

Androgen Receptor (AR) Binding and Genomic Action

The liberated testosterone is a lipophilic molecule that readily diffuses across the cell membranes of target tissues, including skeletal muscle, bone, prostate, skin, and cells within the central nervous system.[6] Once inside the cell's cytoplasm, it binds to a specific intracellular protein known as the androgen receptor (AR). This binding event induces a conformational change in the AR, causing it to dissociate from heat shock proteins and translocate into the cell nucleus.[6]

Inside the nucleus, the testosterone-AR complex functions as a transcription factor. It binds to specific DNA sequences, termed hormone response elements (HREs), located in the promoter regions of androgen-responsive genes.[6] This binding modulates gene transcription, either upregulating or downregulating the synthesis of specific proteins. This genomic action is the fundamental mechanism through which testosterone produces its wide-ranging physiological effects, such as stimulating muscle protein synthesis, promoting erythropoiesis, and influencing male sexual development.[6]

Metabolic Bifurcation: 5α-Reduction and Aromatization

The physiological response to testosterone is complicated by its metabolism into two other potent steroid hormones. This metabolic bifurcation creates a spectrum of effects and is a critical consideration in clinical management.

1. 5α-Reduction to Dihydrotestosterone (DHT): In certain tissues, including the prostate, skin, and hair follicles, the enzyme 5α-reductase converts testosterone into 5α-dihydrotestosterone (DHT).[3] DHT is a more potent androgen than testosterone, binding to the AR with approximately 2.5 times greater affinity.[8] It is the primary mediator of androgenic effects on the development of external male genitalia during fetal development and is responsible for prostate growth, sebum production (leading to acne), and the progression of androgenic alopecia (male pattern baldness) in adulthood.[3]
2. Aromatization to Estradiol (E2): In other tissues, particularly adipose tissue, the brain, and bone, the enzyme aromatase (cytochrome P450 19A1) converts testosterone into the estrogen, estradiol (E2).[3] This conversion is responsible for many of the estrogenic side effects observed during testosterone therapy, such as gynecomastia (the development of breast tissue in men) and fluid retention.[3] However, estradiol also plays crucial physiological roles in men, including the maintenance of bone mineral density, regulation of libido, and negative feedback control of the hypothalamic-pituitary-gonadal axis.[11]

The clinical management of a patient on Testosterone Enanthate therapy is therefore not simply the management of a single hormone. It requires an understanding of the complex interplay between testosterone, DHT, and estradiol. The metabolic pathways that produce DHT and E2 represent potential therapeutic targets. For instance, the common off-label co-administration of aromatase inhibitors (e.g., anastrozole) is a direct attempt to mitigate the estrogenic side effects of testosterone therapy by blocking its conversion to estradiol.[3] Similarly, 5α-reductase inhibitors (e.g., finasteride) are used to manage conditions driven by DHT, such as benign prostatic hyperplasia and androgenic alopecia. This reveals that effective androgen therapy often involves modulating a multi-hormonal system to optimize therapeutic benefits while minimizing adverse effects.

Pharmacodynamics

The administration of Testosterone Enanthate results in a wide array of physiological changes, broadly categorized as androgenic and anabolic effects.

Anabolic and Androgenic Effects

Androgenic effects are primarily related to the growth, development, and maintenance of male primary and secondary sexual characteristics. This includes the maturation of the penis, scrotum, prostate, and seminal vesicles, as well as the development of male hair patterns (facial, pubic, axillary), laryngeal enlargement leading to voice deepening, and alterations in fat distribution.[3] Anabolic effects relate to the promotion of tissue growth and include increased nitrogen retention in muscles, which is a key marker of protein synthesis and muscle growth.[1] Testosterone also stimulates erythropoiesis, leading to an increase in red blood cell count and hemoglobin levels, and plays a vital role in maintaining and increasing bone mineral density.[6]

Hypothalamic-Pituitary-Gonadal (HPG) Axis Suppression

The human body regulates testosterone production through a sophisticated negative feedback loop involving the hypothalamus, pituitary gland, and gonads (testes). When exogenous testosterone is administered, the elevated serum levels are detected by the hypothalamus and pituitary gland.[6] This leads to a downregulation in the secretion of gonadotropin-releasing hormone (GnRH) from the hypothalamus. The reduction in GnRH, in turn, suppresses the pituitary's release of luteinizing hormone (LH) and follicle-stimulating hormone (FSH).[6] Since LH is the primary signal for the testes to produce testosterone and FSH is crucial for spermatogenesis, their suppression leads to a shutdown of endogenous testosterone production and a significant reduction in sperm count, potentially causing testicular atrophy and infertility with prolonged use.[1] This feedback inhibition is the basis for its investigation as a male contraceptive.[1]

Pharmacokinetics

The pharmacokinetic profile of Testosterone Enanthate is defined by its slow absorption, extensive distribution, metabolic conversion, and eventual elimination.

Absorption and Distribution

The key to Testosterone Enanthate's long-acting nature is the "depot effect" created by its formulation. When injected into muscle or subcutaneous tissue, the oil-based vehicle forms a localized reservoir from which the highly lipophilic Testosterone Enanthate is gradually absorbed into the systemic circulation.[3] This slow-release mechanism obviates the need for daily administration. Once in the bloodstream, testosterone is extensively bound to plasma proteins. Approximately 98% of circulating testosterone is bound, primarily to sex hormone-binding globulin (SHBG) and, to a lesser extent, albumin. Only the small, unbound (free) fraction of approximately 2% is biologically active and able to enter target cells.[8] The volume of distribution following intravenous administration of testosterone is approximately 1 L/kg.[8]

Metabolism and Elimination

As previously described, the metabolism of testosterone is a complex process. It is converted to its major active metabolites, DHT and estradiol, in various tissues.[8] The parent compound and its metabolites are further processed, primarily in the liver, into inactive 17-keto steroids.[8] The elimination of these metabolites occurs predominantly through the kidneys. Approximately 90% of an administered dose is excreted in the urine as glucuronic and sulfuric acid conjugates. A smaller fraction, around 6%, is eliminated in the feces, mostly in an unconjugated form.[8]

Pharmacokinetic Profile and Fluctuations

Testosterone Enanthate exhibits a long elimination half-life of approximately 4.5 days and a mean residence time in the body of 8.5 days following intramuscular depot injection.[3] This profile supports a dosing interval of once every one to four weeks.[3] However, this intermittent dosing schedule creates a significant clinical challenge: large fluctuations in serum testosterone concentrations. Following an injection, serum testosterone levels rise sharply, often reaching supraphysiological peaks within the first 24-48 hours.[8] These levels then steadily decline over the subsequent days and weeks, often falling to low-normal or even sub-physiological levels before the next scheduled dose.[3]

This "peak-and-trough" pattern represents a paradox: while the active molecule is bioidentical testosterone, the delivery system creates a profoundly un-physiological pharmacokinetic profile that does not mimic the body's natural diurnal rhythm. This hormonal instability can be experienced by patients as unpleasant fluctuations in mood, energy levels, and libido, corresponding to the rising and falling hormone levels.[13] This significant limitation of traditional intramuscular depot injections has been a primary driver for the development of alternative delivery systems, such as transdermal gels and subcutaneous injections, which aim to provide more stable and physiological serum testosterone concentrations.[13]

Table 2.1: Key Pharmacokinetic Parameters of Testosterone Enanthate

Parameter	Value / Description	Source(s)
Route of Administration	Intramuscular (IM) or Subcutaneous (SC) Depot Injection	3
Elimination Half-Life	Approximately 4.5 days	3
Mean Residence Time	Approximately 8.5 days	3
Typical Dosing Interval	Once every 1 to 4 weeks	3
Time to Peak Concentration (Tmax)	24 to 48 hours post-injection	8
Serum Level Fluctuation	Characterized by initial supraphysiological peaks followed by a decline to sub-physiological trough levels, creating a "peak-and-trough" effect.	3

Clinical Efficacy and Therapeutic Applications

FDA-Approved Indications

The U.S. Food and Drug Administration (FDA) has approved Testosterone Enanthate for a specific set of conditions where a deficiency or absence of endogenous testosterone has been definitively established.

Male Hypogonadism

This is the primary and most common indication for Testosterone Enanthate. The diagnosis must be confirmed by demonstrating low serum testosterone concentrations on at least two separate morning measurements, in conjunction with clinical signs and symptoms.[14] It is approved for two distinct types of hypogonadism:

1. Primary Hypogonadism (Congenital or Acquired): This form is characterized by testicular failure. The testes are unable to produce adequate testosterone despite normal or elevated levels of pituitary gonadotropins (LH and FSH). Causes include genetic conditions like Klinefelter's syndrome, or acquired damage from cryptorchidism, bilateral torsion, orchitis, orchiectomy, chemotherapy, or toxic damage from alcohol or heavy metals.[7]
2. Hypogonadotropic Hypogonadism (Congenital or Acquired): This form results from a failure of the hypothalamus or pituitary gland. The testes are functional but do not receive the necessary hormonal signals (LH and FSH) to produce testosterone. Causes include idiopathic gonadotropin or LHRH deficiency, or pituitary-hypothalamic injury from tumors, trauma, or radiation.[7] Completed Phase 4 clinical trials have specifically supported its efficacy in treating idiopathic hypogonadotropic hypogonadism.[17]

Delayed Puberty in Males

Testosterone Enanthate may be used to stimulate the onset of puberty in carefully selected adolescent males with clearly delayed puberty.[3] This indication is typically reserved for patients with a familial pattern of delayed puberty who are not responding to psychological support and where a pathological disorder has been ruled out.[12] The use in this context is a delicate balancing act. While the therapy can induce the development of secondary sexual characteristics, a significant iatrogenic risk exists. Androgens accelerate bone maturation, and if this process outpaces linear growth, it can lead to premature fusion of the epiphyseal growth plates.[12] This could permanently compromise the patient's final adult height. Therefore, treatment must be short-term, use conservative doses, and involve rigorous monitoring, including regular X-rays of the hand and wrist to assess bone age, to mitigate this risk.[14]

Metastatic Breast Cancer in Females

Testosterone Enanthate has a niche indication as a secondary palliative treatment for women with advancing, inoperable metastatic (skeletal) mammary cancer.[1] It is typically considered for women who are one to five years postmenopausal and have a hormone-responsive tumor.[8] The exact mechanism is not fully understood but is thought to involve counteracting estrogen activity and slowing tumor growth.[18] It is important to note that this is not a first-line treatment and its use should be determined by an oncologist with expertise in this area.[12]

Off-Label and Investigational Uses

A significant portion of Testosterone Enanthate use occurs outside of its narrow FDA-approved indications, reflecting a broad range of clinical needs and patient demands.

Masculinizing Hormone Therapy

One of the most common and widely accepted off-label uses is in masculinizing hormone therapy for transgender men as part of gender-affirming care.[3] It is used to induce the development of masculine secondary sexual characteristics, such as facial and body hair growth, voice deepening, muscle mass redistribution, and cessation of menses.[11] Studies have demonstrated that subcutaneous administration is a safe, effective, and well-tolerated alternative to intramuscular injections for this population, potentially offering a more stable hormonal profile and greater convenience.[15]

Male Contraception

Testosterone Enanthate has been investigated as a potential male hormonal contraceptive. Clinical research has shown that weekly intramuscular injections (e.g., 250 mg) can suppress the HPG axis sufficiently to induce azoospermia (absence of sperm) or severe oligospermia (very low sperm count) in a majority of men.[1] A critical finding from these trials is a significant ethnic variation in response: over 95% of Asian men achieved azoospermia, whereas only 40-70% of Caucasian men did.[1] This suggests underlying genetic or physiological differences in the sensitivity of the HPG axis to exogenous androgen suppression, posing a challenge to its development as a universally reliable contraceptive.

Sarcopenia and Osteoporosis (Age-Related Decline)

The use of testosterone to combat age-related declines in muscle mass (sarcopenia) and bone density (osteoporosis) is perhaps the most widespread and controversial off-label application. As men age, testosterone levels naturally decline, which is correlated with unfavorable changes in body composition, including loss of muscle and bone.[21] Numerous studies and meta-analyses have confirmed that testosterone replacement therapy effectively increases lean body mass and muscle strength in older men and those with chronic diseases.[23] Similarly, testosterone therapy can increase bone mineral density.[26]

However, a crucial gap in the evidence exists. While muscle mass and strength may improve, the data showing that this translates into improved physical function, reduced risk of falls, or a lower incidence of fractures is inconsistent or lacking.[24] This disconnect between surrogate markers (muscle mass) and hard clinical outcomes (fractures) is a key reason for regulatory caution. The FDA has explicitly stated that the safety and efficacy of testosterone have not been established for treating "age-related hypogonadism" and that it should not be used merely to improve body composition in the absence of a classical hypogonadal condition.[7] This creates a significant divide between regulatory guidance and a burgeoning clinical practice driven by direct-to-consumer advertising and the anti-aging industry, which often promotes testosterone for non-specific symptoms like low energy and fatigue.[29] This off-label use generates substantial healthcare costs and exposes individuals to risks without a proven benefit for these indications.[29]

Performance and Physique Enhancement

Due to its potent anabolic properties, Testosterone Enanthate is widely used non-medically by athletes and bodybuilders to increase muscle mass, strength, and performance.[3] This use is illicit in most sporting contexts and is generally considered abuse.[3] It typically involves the administration of supraphysiological doses, often far exceeding the therapeutic range, which significantly increases the risk of serious adverse health effects.[31] This widespread non-medical use has necessitated the development of sophisticated analytical methods to detect testosterone and its metabolites for doping control in sports and forensic applications.[1]

Safety, Tolerability, and Risk Management

Adverse Effects

The adverse effect profile of Testosterone Enanthate is extensive and directly related to its pharmacological actions and metabolic pathways. Effects can be categorized by their underlying mechanism.

• Androgenic Effects: These are direct consequences of androgen receptor stimulation. Common effects include acne, oily skin (seborrhea), and increased growth of facial and body hair (hirsutism).[3] It can also accelerate androgenic alopecia (male pattern baldness) in genetically predisposed individuals.[10] In women, these effects manifest as virilization, which includes deepening of the voice, clitoral hypertrophy, and menstrual irregularities. These changes, particularly voice deepening, can be irreversible even after discontinuation of the drug, making it a significant concern for female patients.[1]
• Estrogenic Effects: These arise from the aromatization of testosterone to estradiol. The most prominent effects are gynecomastia (painful or enlarged breast tissue in males) and edema, which is caused by estrogen-mediated sodium and water retention.[3] Edema can be particularly dangerous for patients with pre-existing cardiac, renal, or hepatic disease.[7]
• Cardiovascular Effects: Testosterone therapy has several important cardiovascular implications. It is known to cause a class-wide increase in blood pressure (hypertension).[32] It also stimulates erythropoiesis, leading to an increase in red blood cell count, hematocrit, and hemoglobin, a condition known as polycythemia.[7] This increases blood viscosity and elevates the risk of thromboembolic events such as stroke and myocardial infarction.[7] Post-marketing reports have confirmed an association with venous thromboembolism (VTE), including deep vein thrombosis (DVT) and pulmonary embolism (PE).[7] Furthermore, it can cause adverse changes in lipid profiles (dyslipidemia), typically characterized by a decrease in high-density lipoprotein (HDL) cholesterol and an increase in low-density lipoprotein (LDL) cholesterol.[1]
• Endocrine and Reproductive Effects: Due to HPG axis suppression, therapy can lead to decreased spermatogenesis, oligospermia, and testicular atrophy, potentially resulting in infertility.[6] In men with pre-existing benign prostatic hyperplasia (BPH), testosterone can worsen lower urinary tract symptoms such as urinary frequency and urgency.[7] Priapism (prolonged, painful erections) is a rare but serious side effect.[14]
• Hepatic Effects: While Testosterone Enanthate is not a 17-alpha-alkylated steroid and thus carries a lower risk of hepatotoxicity than oral anabolic steroids, prolonged use of high doses has been associated with serious hepatic adverse effects, including peliosis hepatis (blood-filled cysts in the liver) and hepatic neoplasms such as adenomas and hepatocellular carcinoma.[12] Elevations in liver function tests can also occur.[32]
• Psychiatric Effects: The influence of testosterone on the central nervous system can lead to a range of psychiatric effects. These include changes in libido (increased or decreased), mood swings, irritability, aggression, anger, anxiety, and depression.[6] In clinical trials for some testosterone products, suicidal ideation and behavior have been reported.[7]
• Injection Site Reactions: Local reactions at the site of injection are common and include pain, redness, swelling, bruising, and irritation.[18]

Table 4.1: Common and Serious Adverse Effects of Testosterone Enanthate

System Organ Class	Adverse Effect	Potential Mechanism	Clinical Notes / Monitoring
Cardiovascular	Hypertension	Androgenic/Fluid Retention	Monitor blood pressure regularly at baseline and during therapy.32
	Polycythemia (Increased Hematocrit)	Stimulation of Erythropoiesis	Check hematocrit at baseline, at 3-6 months, then annually. Discontinue if hematocrit >54%.7
	Venous Thromboembolism (DVT, PE)	Prothrombotic effects, Polycythemia	Evaluate patients for signs/symptoms of VTE. Discontinue if suspected.7
	Dyslipidemia (Decreased HDL, Increased LDL)	Androgenic effect on hepatic lipase	Monitor lipid profile periodically.7
Endocrine/Reproductive	Gynecomastia	Estrogenic (Aromatization)	Clinical monitoring. May require dose adjustment or addition of an aromatase inhibitor.3
	Testicular Atrophy, Oligospermia	HPG Axis Suppression	Counsel patients on potential for infertility. Effect may be reversible.14
	Worsening of BPH	Androgenic (DHT-mediated)	Monitor for worsening urinary symptoms in men with BPH.7
	Virilization (in women)	Androgenic	Monitor for voice changes, hirsutism, clitoromegaly. Discontinue at first sign to prevent irreversibility.12
Dermatologic	Acne, Oily Skin	Androgenic (Sebum production)	Common, especially at initiation of therapy. Manage with standard dermatologic care.32
	Androgenic Alopecia	Androgenic (DHT-mediated)	Counsel genetically predisposed patients on this risk.33
Psychiatric	Mood Swings, Aggression, Depression	Central Nervous System Effects	Monitor for changes in mood and behavior. Counsel patients and caregivers.7
Hepatic	Elevated Liver Enzymes	Hepatocellular effects	Monitor liver function tests periodically. Rare risk of serious events with high doses.12
Musculoskeletal	Premature Epiphyseal Closure (in adolescents)	Androgenic	Monitor bone age with X-rays every 6 months during treatment for delayed puberty.14

Contraindications

The use of Testosterone Enanthate is strictly prohibited in certain patient populations due to an unacceptable risk of harm. Absolute contraindications include:

• Men with known or suspected carcinoma of the prostate or breast.[1]
• Women who are pregnant, may become pregnant, or are breastfeeding. Androgens can cause profound virilization of the external genitalia of a female fetus.[12]
• Individuals with a known hypersensitivity to Testosterone Enanthate or any of its excipients, such as sesame oil, which is a common vehicle in injectable formulations.[7]
• Patients with pre-existing hypercalcemia.[18]
• Patients with severe cardiac, hepatic, or renal disease, where the risk of androgen-induced fluid retention could lead to severe complications like congestive heart failure.[33]

Warnings and Precautions

Beyond absolute contraindications, there are several significant risks that require careful patient selection and diligent monitoring during therapy.

• Prostate Health: Patients with BPH should be monitored for worsening urinary symptoms. All men should be evaluated for prostate cancer with a digital rectal exam and prostate-specific antigen (PSA) measurement before initiating therapy and monitored periodically thereafter.[7]
• Sleep Apnea: Treatment with testosterone may potentiate or unmask sleep apnea, particularly in patients with risk factors such as obesity or chronic lung disease.[7]
• Hypercalcemia: The risk of hypercalcemia is increased in patients with cancer, especially with bony metastases, and in immobilized patients, due to stimulation of osteolysis. Serum calcium levels should be monitored regularly in these at-risk populations.[12]
• Fluid and Electrolyte Balance: Androgens promote sodium and water retention, requiring cautious use in patients with conditions that could be exacerbated by fluid overload.[7]

Misuse and Dependence

Testosterone Enanthate is subject to misuse and abuse, particularly for non-medical purposes like athletic performance and physique enhancement.[7] This typically involves using doses much higher than those prescribed for therapeutic indications, often in combination with other AAS.[31] Such abuse is associated with serious and potentially irreversible health consequences, including major cardiovascular events (heart attack, stroke, heart disease), liver disease, and significant psychiatric disturbances such as severe aggression ("roid rage"), hostility, and addiction.[31]

Upon abrupt cessation after a period of abuse, individuals may experience a withdrawal syndrome characterized by depression, fatigue, irritability, loss of appetite, and decreased libido. These symptoms can persist for weeks to months, reflecting the profound disruption of the endogenous hormonal axis.[20]

Regulatory Status and Prescribing Information

Controlled Substance Classification

In the United States, Testosterone Enanthate is regulated under the Controlled Substances Act (CSA). By virtue of being an anabolic steroid chemically and pharmacologically related to testosterone, it is classified as a Schedule III controlled substance.[2] This classification is reserved for drugs with a currently accepted medical use in treatment, but which also possess a moderate to low potential for physical and psychological dependence.[40] This status imposes stringent legal requirements on manufacturing, prescribing, dispensing, and record-keeping to prevent diversion and abuse.

Recent FDA Labeling Changes (February/March 2025)

In early 2025, the FDA mandated significant, class-wide labeling changes for all prescription testosterone products, including Testosterone Enanthate. This regulatory action was based on a comprehensive review of new evidence from the large-scale TRAVERSE (NCT03518034) clinical trial and several post-market ambulatory blood pressure monitoring (ABPM) studies.[34] This update represents a fundamental paradigm shift in the regulatory and clinical understanding of testosterone's cardiovascular risk profile.

For years, the risk-benefit discussion surrounding testosterone therapy was dominated by a prominent boxed warning (black box warning) regarding a potential increased risk of major adverse cardiovascular events (MACE), such as heart attack and stroke.[34] This warning, based on earlier, less definitive data, likely contributed to apprehension among both patients and prescribers. The TRAVERSE trial, a robust, randomized, placebo-controlled study in over 5,000 hypogonadal men with pre-existing or high risk of cardiovascular disease, provided higher-quality evidence. The trial found that testosterone replacement therapy was non-inferior to placebo with respect to the incidence of MACE.[34] Based on these findings, the FDA mandated the

removal of the boxed warning related to an increased risk of adverse cardiovascular outcomes from all testosterone product labels.[42]

However, the same body of evidence identified a different, more specific, and consistent risk. The post-market ABPM studies, along with data from the TRAVERSE trial, confirmed that testosterone products as a class can cause clinically meaningful increases in systolic and diastolic blood pressure.[34] Consequently, the FDA required the addition of a

new class-wide warning about increases in blood pressure to all product labels.[34]

This regulatory evolution moves the clinical focus from a generalized fear of cardiovascular catastrophe to a more specific and actionable strategy of active risk management. The clinical imperative is no longer simply to be wary of heart attacks but to diligently monitor and manage blood pressure in all patients receiving testosterone therapy. This nuanced, evidence-driven approach is expected to reshape prescribing practices and patient monitoring protocols. The FDA also retained the "limitation of use" language, reiterating that testosterone products are not approved for the treatment of age-related hypogonadism.[34]

Commercial Formulations

The commercial landscape for Testosterone Enanthate has evolved to meet clinical needs for improved convenience and tolerability.

• Current Brand Names: The primary brand name for Testosterone Enanthate in the U.S. is Xyosted, which is a subcutaneous auto-injector. Generic formulations for intramuscular injection are also widely available.[4]
• Discontinued Brand Names: The originator brand, Delatestryl, is no longer marketed in the United States, though the name is still commonly used to refer to the drug.[4]
• Available Dosage Forms and Strengths:
• Xyosted (subcutaneous solution): Available in single-dose auto-injectors containing 50 mg/0.5mL, 75 mg/0.5mL, or 100 mg/0.5mL.[16]
• Generic (intramuscular solution): Typically available in multi-dose vials at a concentration of 200 mg/mL.[16]

The evolution from traditional vials requiring manual syringe preparation for deep intramuscular injection (Delatestryl, generics) to a modern subcutaneous auto-injector (Xyosted) directly reflects a response to the clinical limitations of the older formulations. Intramuscular injections can be painful, inconvenient, and require either a clinical visit or significant patient training.[15] The development of a pre-filled, single-use auto-injector for subcutaneous administration addresses these issues by providing a less painful, more convenient method that patients can easily self-administer at home.[45] Furthermore, subcutaneous administration may offer a more favorable pharmacokinetic profile with less pronounced peaks and troughs compared to the intramuscular route, potentially improving tolerability and stability of mood and energy levels.[15] This trend in pharmaceutical innovation is clearly driven by the need to enhance patient adherence, convenience, and the overall therapeutic index of the drug.

Significant Drug-Drug Interactions

The administration of Testosterone Enanthate can lead to several clinically significant drug-drug interactions, requiring careful monitoring and potential dosage adjustments of concomitant medications.

Clinically Relevant Interactions

• Anticoagulants: Testosterone and other androgens can enhance the anticoagulant effect of coumarin derivatives like warfarin. This interaction is considered major and can increase the risk of bleeding. Patients on oral anticoagulants require more frequent monitoring of their International Normalized Ratio (INR) and prothrombin time, particularly upon initiation, dose adjustment, or discontinuation of testosterone therapy. A reduction in the anticoagulant dosage may be necessary.[7]
• Antidiabetic Agents: Androgens can improve glucose tolerance and increase insulin sensitivity. This may lead to a decrease in blood glucose levels and a reduced requirement for insulin or oral hypoglycemic agents in diabetic patients. Close monitoring of blood glucose is essential, and adjustment of the antidiabetic medication dosage may be required to avoid hypoglycemia.[7]
• Corticosteroids: The concurrent use of testosterone with corticosteroids or adrenocorticotropic hormone (ACTH) can potentiate fluid retention and edema. This combination should be administered with caution, especially in patients with underlying cardiac, renal, or hepatic disease, as it can exacerbate fluid overload and lead to complications like congestive heart failure.[7]
• P-glycoprotein (P-gp) Substrates: There is evidence to suggest that testosterone can act as an inhibitor of the P-gp efflux transporter. This can lead to increased plasma concentrations of drugs that are P-gp substrates, thereby increasing their potential for toxicity. For example, co-administration with dabigatran or rivaroxaban may increase bleeding risk, and the interaction with tolvaptan is rated as major, potentially requiring a dose reduction of tolvaptan.[47]
• Laboratory Test Interactions: Androgens can affect the levels of certain binding proteins in the blood. Specifically, they may decrease the concentrations of thyroxine-binding globulin (TBG). This results in decreased total T4 serum concentrations and increased resin uptake of T3 and T4. However, free thyroid hormone concentrations (free T3 and free T4) typically remain unchanged, and there is usually no clinical evidence of thyroid dysfunction. It is important for clinicians to be aware of this potential interference when interpreting thyroid function tests.[7]

Table 6.1: Major and Moderate Drug-Drug Interactions with Testosterone Enanthate

Interacting Drug / Class	Interaction Severity	Mechanism of Interaction	Clinical Management Recommendation	Source(s)
Anticoagulants (e.g., Warfarin)	Major / Moderate	Pharmacodynamic: Enhanced anticoagulant effect, reduced procoagulant factors.	Monitor INR and prothrombin time frequently, especially at initiation/discontinuation of therapy. Reduce anticoagulant dose as needed.	7
Antidiabetic Agents (e.g., Insulin, Sulfonylureas)	Moderate	Pharmacodynamic: Improved insulin sensitivity, decreased blood glucose.	Monitor blood glucose levels closely. Adjust dose of antidiabetic medication as needed to prevent hypoglycemia.	16
Corticosteroids / ACTH	Moderate	Pharmacodynamic: Additive fluid retention effects.	Use with caution, particularly in patients with cardiac, renal, or hepatic disease. Monitor for edema.	7
P-gp Substrates (e.g., Tolvaptan, Dabigatran)	Major (Tolvaptan) / Moderate	Pharmacokinetic: Inhibition of P-gp efflux pump, leading to increased substrate concentration.	Monitor for signs of toxicity of the co-administered drug. Dose reduction of the P-gp substrate may be required.	47

Synthesis and Future Directions

Concluding Expert Summary

Testosterone Enanthate remains a cornerstone of androgen replacement therapy, a status it has held for over half a century. Its enduring utility is rooted in its straightforward chemistry as a prodrug that, through a simple depot injection, provides a sustained release of bioidentical testosterone. It is an unequivocally effective therapy for restoring physiological androgen levels in men with clinically and biochemically confirmed hypogonadism, with well-documented benefits for sexual function, mood, muscle mass, and bone density.

The primary clinical challenge associated with Testosterone Enanthate has always been the un-physiological pharmacokinetic profile created by intermittent depot injections. The resultant "peak-and-trough" fluctuations in serum levels can compromise patient well-being and contribute to side effects. The risk profile of the drug is extensive but well-characterized, encompassing androgenic, estrogenic, and metabolic consequences. This profile was recently re-contextualized by a landmark FDA labeling update in 2025, which shifted the focus of cardiovascular concern away from a generalized risk of major adverse cardiac events and toward the specific, measurable, and manageable risk of hypertension. This evolution reflects a maturation in the understanding of testosterone's systemic effects, moving clinical practice toward more nuanced risk management rather than risk avoidance.

Ultimately, the successful use of Testosterone Enanthate hinges on appropriate patient selection, diligent monitoring, and a clear understanding of its risk-benefit profile. Its application should be restricted to patients with a confirmed diagnosis of hypogonadism. Its widespread off-label use for non-specific symptoms of aging remains controversial and is not supported by current regulatory guidance, highlighting a critical need for continued patient and provider education.

Areas of Ongoing Research

The future of Testosterone Enanthate and androgen therapy, in general, is being shaped by research focused on optimizing delivery, exploring novel therapeutic applications, and further clarifying long-term safety.

• Optimizing Delivery Systems: A major thrust of current research is the refinement of delivery methods to mitigate the pharmacokinetic limitations of traditional intramuscular injections. The development and study of subcutaneous testosterone enanthate auto-injectors (SCTE-AI) is a prime example. Clinical trials have focused on confirming the safety, efficacy, and pharmacokinetic stability of this route, which offers the dual benefits of improved patient convenience through self-administration and the potential for more stable serum testosterone levels.[15] Further research, including head-to-head trials comparing subcutaneous versus intramuscular administration in diverse populations such as transgender men, will continue to refine dosing strategies and establish the relative advantages of each route.[48]
• Expanding Therapeutic Indications: Investigators are exploring the use of testosterone in novel and sometimes paradoxical ways. A prominent example is in oncology, where the "Transformer" trial (NCT02286921) is investigating "bipolar androgen therapy" (BAT)—the cyclical administration of high-dose testosterone—as a strategy to re-sensitize or overcome resistance in castration-resistant prostate cancer.[49] Another trial, NCT06594926, is examining cyclical testosterone in combination with the androgen receptor inhibitor darolutamide in non-metastatic castration-resistant prostate cancer, representing a potential new treatment paradigm.[51]
• Clarifying Long-Term Safety and Efficacy: While the TRAVERSE trial provided invaluable data on cardiovascular safety over a median follow-up of 33 months, questions regarding the very long-term effects of testosterone therapy remain.[34] Further research is needed to definitively establish the long-term impact on prostate health, including the risk of prostate cancer progression. Additionally, while testosterone is known to increase bone mineral density, large-scale, long-term trials are still required to determine if this translates into a clinically meaningful reduction in fracture risk in aging men.[26] Studies exploring synergistic effects, such as combining testosterone with bisphosphonates like alendronate for osteoporosis ( NCT01460654), may help define its role as an adjunctive therapy for bone health in hypogonadal men.[52] This ongoing research will continue to refine the risk-benefit calculus and guide the appropriate and safe use of Testosterone Enanthate for decades to come.

Works cited

1. Testosterone enanthate CAS#: 315-37-7 - ChemicalBook, accessed September 11, 2025, https://m.chemicalbook.com/ProductChemicalPropertiesCB8448727_EN.htm
2. Testosterone Enanthate (NSC 17591, CAS Number: 315-37-7) | Cayman Chemical, accessed September 11, 2025, https://www.caymanchem.com/product/22546/testosterone-enanthate
3. Testosterone enanthate - Wikipedia, accessed September 11, 2025, https://en.wikipedia.org/wiki/Testosterone_enanthate
4. What are the brands of testosterone? - Drugs.com, accessed September 11, 2025, https://www.drugs.com/medical-answers/brands-testosterone-3510863/
5. Testosterone Enanthate | C26H40O3 | CID 9416 - PubChem, accessed September 11, 2025, https://pubchem.ncbi.nlm.nih.gov/compound/Testosterone-Enanthate
6. What is the mechanism of Testosterone Enanthate? - Patsnap Synapse, accessed September 11, 2025, https://synapse.patsnap.com/article/what-is-the-mechanism-of-testosterone-enanthate
7. Untitled - accessdata.fda.gov, accessed September 11, 2025, https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/209863s020lbl.pdf
8. Testosterone enanthate: Uses, Interactions, Mechanism of Action ..., accessed September 11, 2025, https://go.drugbank.com/drugs/DB13944
9. go.drugbank.com, accessed September 11, 2025, https://go.drugbank.com/drugs/DB13944#:~:text=To%20start%20its%20activity%2C%20testosterone,steroids%20through%20two%20different%20pathways.
10. What are the side effects of Testosterone Enanthate? - Patsnap Synapse, accessed September 11, 2025, https://synapse.patsnap.com/article/what-are-the-side-effects-of-testosterone-enanthate
11. Testosterone enanthate – Knowledge and References - Taylor & Francis, accessed September 11, 2025, https://taylorandfrancis.com/knowledge/Medicine_and_healthcare/Pharmaceutical_medicine/Testosterone_enanthate/
12. (Testosterone Enanthate Injection, USP) Multiple Dose Vial DESCRIPTION DELATESTRYL - accessdata.fda.gov, accessed September 11, 2025, https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/009165s034lbl.pdf
13. 8 Comparative pharmacokinetics of 194 mg of testosterone enanthate and... - ResearchGate, accessed September 11, 2025, https://www.researchgate.net/figure/Comparative-pharmacokinetics-of-194-mg-of-testosterone-enanthate-and-200-mg-of_fig7_264848721
14. Testosterone Enanthate Injection, USP C, accessed September 11, 2025, https://pdf.hres.ca/dpd_pm/00071616.PDF
15. Pharmacokinetic Profile of Subcutaneous Testosterone Enanthate Delivered via a Novel, Prefilled Single‐Use Autoinjector: A Phase II Study - Semantic Scholar, accessed September 11, 2025, https://www.semanticscholar.org/paper/Pharmacokinetic-Profile-of-Subcutaneous-Enanthate-a-Kaminetsky-Jaffe/4fbecfb768838dc450c3b75e2fcc7a39ab94ddfb
16. Depo-Testosterone, Aveed, Xyosted (testosterone cypionate ..., accessed September 11, 2025, https://reference.medscape.com/drug/depo-testosterone-aveed-342795
17. Testosterone enanthate Completed Phase 4 Trials for idiopathic Hypogonadotropic Hypogonadism Treatment | DrugBank Online, accessed September 11, 2025, https://go.drugbank.com/drugs/DB13944/clinical_trials?conditions=DBCOND0037480&phase=4&purpose=treatment&status=completed
18. Testosterone Enanthate: Uses, FAQs, Side Effects & More - GoodRx, accessed September 11, 2025, https://www.goodrx.com/testosterone-enanthate/what-is
19. TESTOSTERONE ENANTHATE (testosterone enanthate) - Complete Drug Label Info, PA Forms, & Patient Education (2025) - PrescriberPoint, accessed September 11, 2025, https://prescriberpoint.com/therapies/testosterone-enanthate-82a9813
20. Testosterone Enanthate Uses, Side Effects & Warnings - Drugs.com, accessed September 11, 2025, https://www.drugs.com/mtm/testosterone-enanthate.html
21. Testosterone and Sarcopenia - PMC, accessed September 11, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC6119844/
22. Sarcopenia and Androgens: A Link between Pathology and Treatment - Frontiers, accessed September 11, 2025, https://www.frontiersin.org/journals/endocrinology/articles/10.3389/fendo.2014.00217/full
23. Testosterone Supplementation for Aging-Associated Sarcopenia - ResearchGate, accessed September 11, 2025, https://www.researchgate.net/publication/8996812_Testosterone_Supplementation_for_Aging-Associated_Sarcopenia
24. Testosterone Supplementation on Sarcopenia Components in Chronic Patients: A Systematic Review and Meta-Analysis - ResearchGate, accessed September 11, 2025, https://www.researchgate.net/publication/356294764_Testosterone_Supplementation_on_Sarcopenia_Components_in_Chronic_Patients_A_Systematic_Review_and_Meta-Analysis
25. Relationship between Testosterone and Sarcopenia in Older-Adult Men: A Narrative Review - PMC, accessed September 11, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC9605266/
26. Testosterone Replacement Therapy for Treatment of Osteoporosis in Men - Amazon S3, accessed September 11, 2025, https://s3-eu-west-1.amazonaws.com/science-now.reports/f1000reports/files/9002/12/18/article.pdf
27. Testosterone and Bone Health in Men: A Narrative Review - PMC, accessed September 11, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC7867125/
28. Testosterone Therapy: Review of Clinical Applications - AAFP, accessed September 11, 2025, https://www.aafp.org/pubs/afp/issues/2017/1001/p441.html
29. OFF-LABEL USE AND MISUSE OF TESTOSTERONE, GROWTH HORMONE, THYROID HORMONE, AND ADRENAL SUPPLEMENTS: RISKS AND COSTS OF A GROWING PROBLEM - PubMed, accessed September 11, 2025, https://pubmed.ncbi.nlm.nih.gov/32163313/
30. What is Testosterone Enanthate used for? - Patsnap Synapse, accessed September 11, 2025, https://synapse.patsnap.com/article/what-is-testosterone-enanthate-used-for
31. healthy.kaiserpermanente.org, accessed September 11, 2025, https://healthy.kaiserpermanente.org/health-wellness/drug-encyclopedia/drug.testosterone-enanthate-200-mg-ml-intramuscular-oil.271060#:~:text=Misuse%20or%20abuse%20of%20testosterone,or%20for%20longer%20than%20prescribed.
32. testosterone enanthate 200 mg/mL intramuscular oil - Kaiser Permanente, accessed September 11, 2025, https://healthy.kaiserpermanente.org/health-wellness/drug-encyclopedia/drug.testosterone-enanthate-200-mg-ml-intramuscular-oil.271060
33. Testosterone Enantate 250 mg/ ml Solution for Injection Ampoules - Patient Information Leaflet (PIL) - (emc) | 3733, accessed September 11, 2025, https://www.medicines.org.uk/emc/product/3733/pil
34. FDA issues labeling changes for testosterone products following TRAVERSE, postmarket studies - Urology Times, accessed September 11, 2025, https://www.urologytimes.com/view/fda-issues-label-changes-for-testosterone-products-following-traverse-post-market-studies
35. Marius Pharmaceuticals Helps Drive FDA's Landmark Testosterone Label Update, Removing Black Box Warning - BioSpace, accessed September 11, 2025, https://www.biospace.com/press-releases/marius-pharmaceuticals-helps-drive-fdas-landmark-testosterone-label-update-removing-black-box-warning
36. Testosterone and Alcohol/Food Interactions - Drugs.com, accessed September 11, 2025, https://www.drugs.com/food-interactions/testosterone.html
37. Testosterone Injections: Uses & Side Effects - Cleveland Clinic, accessed September 11, 2025, https://my.clevelandclinic.org/health/drugs/18031-testosterone-injection
38. Testosterone - Molina Healthcare, accessed September 11, 2025, https://www.molinahealthcare.com/providers/oh/medicaid/policies/-/media/Molina/PublicWebsite/PDF/Providers/oh/medicaid/policies/Testosterone-C2270-A.pdf
39. Classification of Three Steroids as Schedule III Anabolic Steroids Under the Controlled Substances Act - Federal Register, accessed September 11, 2025, https://www.federalregister.gov/documents/2009/12/04/E9-28572/classification-of-three-steroids-as-schedule-iii-anabolic-steroids-under-the-controlled-substances
40. Drug Scheduling - DEA.gov, accessed September 11, 2025, https://www.dea.gov/drug-information/drug-scheduling
41. Controlled Substances - Rosalind Franklin University, accessed September 11, 2025, https://www.rosalindfranklin.edu/research/research-support-offices/environmental-health-and-safety/controlled-substances/
42. FDA issues class-wide labeling changes for testosterone products, accessed September 11, 2025, https://www.fda.gov/drugs/drug-safety-and-availability/fda-issues-class-wide-labeling-changes-testosterone-products
43. In Brief: Label Changes for Testosterone Products | The Medical Letter Inc., accessed September 11, 2025, https://secure.medicalletter.org/TML-article-1726d
44. Androgel vs. Delatestryl for Testosterone Replacement - GoodRx, accessed September 11, 2025, https://www.goodrx.com/compare/testim-vs-delatestryl
45. Safety of a New Subcutaneous Testosterone Enanthate Auto-Injector: Results of a 26-Week Study - PubMed, accessed September 11, 2025, https://pubmed.ncbi.nlm.nih.gov/31551193/
46. Post-market safety and efficacy profile of subcutaneous testosterone enanthate-autoinjector: a cohort analysis - PubMed, accessed September 11, 2025, https://pubmed.ncbi.nlm.nih.gov/34007063/
47. The interaction of drugs to treat cardiovascular diseases and testosterone therapy, their effects and characteristics - Journal of Men's Health, accessed September 11, 2025, https://oss.jomh.org/files/article/20210409-244/pdf/25-31%20JOMH343.pdf
48. Study Details | Subcutaneous Testosterone Project | ClinicalTrials.gov, accessed September 11, 2025, https://clinicaltrials.gov/study/NCT02229617
49. Study Results | Testosterone Revival Abolishes Negative Symptoms, Fosters Objective Response and Modulates Enzalutamide Resistance | ClinicalTrials.gov, accessed September 11, 2025, https://www.clinicaltrials.gov/study/NCT02286921?tab=results
50. Study Details | NCT02286921 | Testosterone Revival Abolishes Negative Symptoms, Fosters Objective Response and Modulates Enzalutamide Resistance | ClinicalTrials.gov, accessed September 11, 2025, https://clinicaltrials.gov/study/NCT02286921
51. Study Details | Working Out M0 Bipolar Androgen Therapy - ClinicalTrials.gov, accessed September 11, 2025, https://clinicaltrials.gov/study/NCT06594926?term=testosterone%20enanthate&viewType=Table&rank=9
52. Study Details | NCT01460654 | Testosterone and Alendronate in ..., accessed September 11, 2025, https://clinicaltrials.gov/study/NCT01460654